[Clinical investigation of cefadroxil in pediatric field (author's transl)]. 1981

S Nanri, and K Jozaki, and H Hattori, and M Hotta, and H Akita, and N Yamashita, and K Sunakawa, and T Oikawa, and Y Ichihashi, and H Takahashi, and S Iwata, and T Kori

(1) Cefadroxil powder for syrup was administered in 24 cases of respiratory tract infection and urinary tract infection, and the efficacy was obtained in 21 cases, effective ratio being 87.5%. (2) Clinical effect could be obtained satisfactorily at a daily dose of 10-15 mg/kg divided into 3 times after each meal. (3) As to the side effect, GOT and GPT rose in 1 case, and stomatitis in 1 case, though the patients returned to normal after discontinuation of the drug. (4) Haemophilus appeared by pharyngeal culture after administration of the drug, and attention should be paid on an alteration of pharyngeal flora.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D012141 Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases. Respiratory System Infections,Upper Respiratory Tract Infection,Upper Respiratory Tract Infections,Infections, Respiratory,Infections, Respiratory Tract,Infections, Upper Respiratory,Infections, Upper Respiratory Tract,Respiratory Infections,Upper Respiratory Infections,Infection, Respiratory System,Infection, Respiratory Tract,Respiratory Infection, Upper,Respiratory System Infection,Respiratory Tract Infection
D002434 Cefadroxil Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative. 4-Hydroxycephalexin,5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))-,BL-S 578,BL-S578,Bidocef,Cefadroxil Anhydrous,Cefadroxil Monohydrate,Cephadroxyl,Duricef,S-578,S578,Ultracef,4 Hydroxycephalexin,BL S 578,BL S578,BLS 578,BLS578,S 578
D002506 Cephalexin A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms. 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))-,Cefalexin,Cephalexin Dihydride,Cephalexin Hemihydrate,Cephalexin Hydrochloride,Cephalexin Monohydrate,Cephalexin Monohydrochloride,Cephalexin Monohydrochloride, Monohydrate,Cephalexin, (6R-(6alpha,7alpha(R*)))-Isomer,Cephalexin, (6R-(6alpha,7beta(S*)))-Isomer,Cephalexin, (6R-(6alpha,7beta))-Isomer,Cephalexin, Monosodium Salt,Cephalexin, Monosodium Salt, (6R-(6alpha,7beta))-Isomer,Ceporexine,Palitrex
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004304 Dosage Forms Completed forms of the pharmaceutical preparation in which prescribed doses of medication are included. They are designed to resist action by gastric fluids, prevent vomiting and nausea, reduce or alleviate the undesirable taste and smells associated with oral administration, achieve a high concentration of drug at target site, or produce a delayed or long-acting drug effect. Dosage Form,Form, Dosage,Forms, Dosage
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females

Related Publications

S Nanri, and K Jozaki, and H Hattori, and M Hotta, and H Akita, and N Yamashita, and K Sunakawa, and T Oikawa, and Y Ichihashi, and H Takahashi, and S Iwata, and T Kori
February 1981, The Japanese journal of antibiotics,
S Nanri, and K Jozaki, and H Hattori, and M Hotta, and H Akita, and N Yamashita, and K Sunakawa, and T Oikawa, and Y Ichihashi, and H Takahashi, and S Iwata, and T Kori
October 1979, The Japanese journal of antibiotics,
S Nanri, and K Jozaki, and H Hattori, and M Hotta, and H Akita, and N Yamashita, and K Sunakawa, and T Oikawa, and Y Ichihashi, and H Takahashi, and S Iwata, and T Kori
February 1981, The Japanese journal of antibiotics,
S Nanri, and K Jozaki, and H Hattori, and M Hotta, and H Akita, and N Yamashita, and K Sunakawa, and T Oikawa, and Y Ichihashi, and H Takahashi, and S Iwata, and T Kori
March 1980, The Japanese journal of antibiotics,
S Nanri, and K Jozaki, and H Hattori, and M Hotta, and H Akita, and N Yamashita, and K Sunakawa, and T Oikawa, and Y Ichihashi, and H Takahashi, and S Iwata, and T Kori
April 1980, The Japanese journal of antibiotics,
S Nanri, and K Jozaki, and H Hattori, and M Hotta, and H Akita, and N Yamashita, and K Sunakawa, and T Oikawa, and Y Ichihashi, and H Takahashi, and S Iwata, and T Kori
January 1981, The Japanese journal of antibiotics,
S Nanri, and K Jozaki, and H Hattori, and M Hotta, and H Akita, and N Yamashita, and K Sunakawa, and T Oikawa, and Y Ichihashi, and H Takahashi, and S Iwata, and T Kori
January 1981, The Japanese journal of antibiotics,
S Nanri, and K Jozaki, and H Hattori, and M Hotta, and H Akita, and N Yamashita, and K Sunakawa, and T Oikawa, and Y Ichihashi, and H Takahashi, and S Iwata, and T Kori
January 1981, The Japanese journal of antibiotics,
S Nanri, and K Jozaki, and H Hattori, and M Hotta, and H Akita, and N Yamashita, and K Sunakawa, and T Oikawa, and Y Ichihashi, and H Takahashi, and S Iwata, and T Kori
January 1981, The Japanese journal of antibiotics,
S Nanri, and K Jozaki, and H Hattori, and M Hotta, and H Akita, and N Yamashita, and K Sunakawa, and T Oikawa, and Y Ichihashi, and H Takahashi, and S Iwata, and T Kori
February 1981, The Japanese journal of antibiotics,
Copied contents to your clipboard!